2001 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Kelsen
    Kelsen
  4. Saltz
    Saltz
  5. Norton
    Norton
  6. Bajorin
    Bajorin
  7. Kemeny
    Kemeny
  8. Scher
    Scher
  9. Ilson
    Ilson
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (1218)
  2. Solid Tumor Oncology Division (929)
  3. Survivorship Research (432)
  4. Surgery (399)
  5. Hematologic Malignancies, Division of (340)
  6. Center for Hematologic Malignancies (328)
  7. Gastrointestinal Oncology Service (315)
  8. Epidemiology and Biostatistics (251)
  9. Genitourinary Oncology Service (233)
  10. Biostatistics Service (223)
  1. "antineoplastic combined chemotherapy protocols"
Formats
  1. Journal Article (1861)
  2. Conference Paper (49)
  3. Review (39)
  4. Editorial (17)
  5. Research Letter (15)
  6. Miscellaneous (8)
  7. Correspondence (6)
  8. Guidelines (5)
  9. Book Section (1)
Groups
  1. Department of Medicine (1218)
  2. Solid Tumor Oncology Division (929)
  3. Survivorship Research (432)
  4. Surgery (399)
  5. Hematologic Malignancies, Division of (340)
  6. Center for Hematologic Malignancies (328)

More Groups

People
  1. Nancy Kemeny (90)
  2. Robert Motzer (88)
  3. Clifford Hudis (83)
  4. David Kelsen (83)
  5. Leonard Saltz (79)
  6. Larry Norton (77)

More People

Years
  1. 2025 (46)
  2. 2024 (133)
  3. 2023 (122)
  4. 2022 (90)
  5. 2021 (11)
  6. 2020 (7)

More Years

Publications
  1. Journal of Clinical Oncology (279)
  2. Cancer (171)
  3. Clinical Cancer Research (78)
  4. Seminars in Oncology (59)
  5. Gynecologic Oncology (58)
  6. New England Journal of Medicine (58)

More Publications

Publishers
  1. American Society of Clinical Oncology (294)
  2. Elsevier Inc. (276)
  3. Wiley Blackwell (212)
  4. Springer (167)
  5. Oxford University Press (113)
  6. American Association for Cancer Research (108)

More Publishers

Results (2001)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma
    Journal Article

    MacManus, M. P.; Seymour, J. F.; Tsang, H.; Fisher, R.; Keane, C.; Sabdia, M. B.; Law, S. C.; Gunawardana, J.; Nath, K.; Kazakoff, S. H.; more...
    EBioMedicine (2024)

    Fulltext@MSK | Save
  • Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma
    Journal Article

    Movva, S.; Seier, K.; Avutu, V.; Banks, L. B.; Chan, J.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab
    Journal Article

    Lochrin, S. E.; Buonocore, D. J.; Young, R. J.; Kaley, T. J.; Postow, M. A.; Wolchok, J. D.; Shoushtari, A. N.; Momtaz, P.; Betof Warner, A. S.; Callahan, M. K.
    Pigment Cell & Melanoma Research (2024)

    Fulltext@MSK | Save
  • Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
    Journal Article

    Kopetz, S.; Murphy, D. A.; Pu, J.; Ciardiello, F.; Desai, J.; Van Cutsem, E.; Wasan, H. S.; Yoshino, T.; Saffari, H.; Zhang, X.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: The MyCheckpoint randomized clinical trial
    Journal Article

    Richard, S.; Lesokhin, A. M.; Paul, B.; Kaufman, J. L.; Pianko, M.; Biran, N.; Vij, R.; Doxie, D. B.; Azeem, M. I.; Martillo, M.; more...
    Nature Cancer (2024)

    Fulltext@MSK | Save
  • Acute myeloid leukemia (AML) with chromosome 3 inversion: Biology, management, and clinical outcome
    Review

    Alhajahjeh, A.; Bewersdorf, J. P.; Bystrom, R. P.; Zeidan, A. M.; Shimony, S.; Stahl, M.
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • The NEOLETRIB trial: Neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer
    Journal Article

    Fjermeros, K.; Ghannoum, S.; Geisler, S. B.; Bhargava, S.; Tahiri, A.; Klajic, J.; Lüders, T.; Fongård, M.; Nawaz, M. S.; Bosnjak-Olsen, T.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • Computed tomography-based radiomics with machine learning outperforms radiologist assessment in estimating colorectal liver metastases pathologic response after chemotherapy
    Journal Article

    Karagkounis, G.; Horvat, N.; Danilova, S.; Chhabra, S.; Narayan, R. R.; Barekzai, A. B.; Kleshchelski, A.; Joanne, C.; Gonen, M.; Balachandran, V.; more...
    Annals of Surgical Oncology (2024)

    Fulltext@MSK | Save
  • Adavosertib in combination with olaparib in patients with refractory solid tumors: An open-label, dose-finding, and dose-expansion Phase Ib trial
    Journal Article

    Hamilton, E. P.; Falchook, G. S.; Wang, J. S.; Fu, S.; Oza, A. M.; Imedio, E. R.; Kumar, S.; Ottesen, L.; Mugundu, G. M.; de Bruin, E. C.; more...
    Targeted Oncology (2024)

    Fulltext@MSK | Save
  • Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer
    Journal Article

    Powles, T.; Catto, J. W. F.; Galsky, M. D.; Al-Ahmadie, H.; Meeks, J. J.; Nishiyama, H.; Vu, T. Q.; Antonuzzo, L.; Wiechno, P.; Atduev, V.; more...
    New England Journal of Medicine (2024)

    Fulltext@MSK | Save